Data / Companies / NTRA
Natera, Inc.Nasdaq
NTRA-US · CIK 0001604821 · Services-Medical Laboratories
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$200M$400M$600M$800M
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $752.8M | -$67.0M | -0.47 |
| Q1 FY2026 | $696.6M | -$85.1M | -0.60 |
| Q4 FY2025 | $665.5M | $47.3M | 0.36 |
| Q3 FY2025 | $592.2M | -$87.5M | -0.64 |
Newest filings
All 271| Form | Filed | |
|---|---|---|
| S-8 | 7 Aug 2026 | |
| 10-Q | 7 Aug 2026 | |
| 8-K | 6 Aug 2026 | |
| 8-K | 6 Jul 2026 | |
| 8-K/A | 16 Jun 2026 | |
| 8-K | 16 Jun 2026 | |
| 8-K | 5 Jun 2026 | |
| 10-Q | 8 May 2026 |
Description
- Ticker
- NTRA-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Services-Medical Laboratories
- SIC division
- Services
- CIK
- 0001604821
- Fiscal year ends
- Dec
- Filings held
- 271 since 2014
- 8-K events
- 111
- Shares short
- 5.9M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
5 years · US$ millions
| Fiscal period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Period ending | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K | 10-K | 10-K |
| Report filed | 25 Feb 2022 | 1 Mar 2023 | 29 Feb 2024 | 28 Feb 2025 | 27 Feb 2026 |
| Revenue | 625M | 820M | 1,083M | 1,697M | 2,306M |
| Research and development | 264M | 316M | 321M | 404M | 624M |
| Selling, general and administrative | 511M | 589M | 618M | 841M | 1,177M |
| Operating income | -468M | -541M | -446M | -222M | -310M |
| Operating margin | -74.8% | -66.0% | -41.2% | -13.1% | -13.4% |
| Profit before tax | -471M | -547M | -435M | -190M | -268M |
| Income tax | 1M | 1M | 0M | 1M | -60M |
| Net income | -472M | -548M | -435M | -190M | -208M |
| Net margin | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| Earnings per share, diluted | -5.21 | -5.57 | -3.78 | -1.53 | -1.52 |
| Diluted shares | 91M | 98M | 115M | 125M | 137M |
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2013 and comes with a data plan. Tell us what you need
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $59.0B
- Price
- $410.83
- Price to book
- 32.39×
- Enterprise value
- $58.0B
- Market cap / sales
- 21.80×
- 52-week high
- $425.55
- 52-week low
- $182.65
Profitability
- Operating margin
- -10.7%
- Net margin
- -7.1%
- FCF margin
- 3.1%
- ROE
- -10.6%
- ROE, 3-year average
- -28.3%
- ROCE
- -15.2%
- Interest cover
- -75.89×
Growth
- Sales growth, TTM
- 37.8%
- Sales CAGR, 3 years
- 41.1%
- Sales CAGR, 5 years
- 42.6%
- Sales CAGR, 10 years
- 28.3%
- Price, 1 year
- 113.7%
- Price CAGR, 3 years
- 120.6%
- Price CAGR, 5 years
- 28.5%
Balance sheet
- Cash and equivalents
- $1.1B
- Borrowings
- $80.3M
- Net debt
- -$1.0B
- Debt to equity
- 0.04×
- Shareholders' equity
- $1.8B
- Total assets
- $2.7B
- Net debt change, 1 year
- -$91.5M
Shareholders
- Shares outstanding
- 143,612,000
- Share count, last 12 months
- 5.0%
- Years FCF margin > 20%, of 5
- 0
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2013 and comes with a data plan. Tell us what you need
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
By product, FY2025
- Product$2.3B 99.6%
- Licensing and other$10.3M 0.4%
3 years held, FY2023 to FY2025
By region, FY2025
- United States$2.3B 98.2%
- Europe, Middle East, India, and Africa$24.5M 1.1%
- Americas, excluding U.S.$9.4M 0.4%
- Asia Pacific and Other$8.0M 0.3%
3 years held, FY2023 to FY2025
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2013 and comes with a data plan. Tell us what you need
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 | |
| 6 Jul 2026 | 8-K | Leadership change | 5.02 | |
| 16 Jun 2026 | 8-K/A | Leadership change | 5.02, 9.01 | |
| 16 Jun 2026 | 8-K | Leadership changeShareholder vote | 5.02, 5.07, 9.01 | |
| 5 Jun 2026 | 8-K | Leadership change | 5.02, 9.01 | |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 | |
| 1 Apr 2026 | 8-K | Leadership change | 5.02, 9.01 | |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 | |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 | |
| 5 Dec 2025 | 8-K | Share saleOther events | 3.02, 8.01, 9.01 | |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 | |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 | |
| 18 Jun 2025 | 8-K | Leadership changeShareholder vote | 5.02, 5.07, 9.01 | |
| 8 May 2025 | 8-K | Results | 2.02, 9.01 | |
| 12 Mar 2025 | 8-K | Leadership change | 5.02, 9.01 | |
| 27 Feb 2025 | 8-K | Results | 2.02, 9.01 | |
| 13 Jan 2025 | 8-K | Results | 2.02, 9.01 | |
| 6 Dec 2024 | 8-K | Leadership change | 5.02 | |
| 12 Nov 2024 | 8-K | Results | 2.02, 9.01 | |
| 8 Aug 2024 | 8-K | Results | 2.02, 9.01 | |
| 22 Jul 2024 | 8-K | Other events | 8.01 | |
| 18 Jun 2024 | 8-K | Leadership changeShareholder vote | 5.02, 5.07, 9.01 | |
| 9 May 2024 | 8-K | Results | 2.02, 9.01 | |
| 28 Feb 2024 | 8-K | Results | 2.02, 9.01 | |
| 22 Jan 2024 | 8-K | Other events | 8.01, 9.01 | |
| 9 Jan 2024 | 8-K | Results | 2.02, 9.01 | |
| 8 Nov 2023 | 8-K | Results | 2.02, 9.01 | |
| 7 Sep 2023 | 8-K | Material agreementOther events | 1.01, 8.01, 9.01 | |
| 3 Aug 2023 | 8-K | Results | 2.02, 9.01 | |
| 15 Jun 2023 | 8-K | Shareholder vote | 5.07 | |
| 9 May 2023 | 8-K | Results | 2.02, 9.01 | |
| 21 Apr 2023 | 8-K | Leadership change | 5.02, 9.01 | |
| 13 Mar 2023 | 8-K | Investor update | 7.01 | |
| 28 Feb 2023 | 8-K | Results | 2.02, 9.01 | |
| 23 Feb 2023 | 8-K | Leadership change | 5.02, 9.01 | |
| 16 Nov 2022 | 8-K | Material agreementOther events | 1.01, 8.01, 9.01 | |
| 8 Nov 2022 | 8-K | Results | 2.02, 9.01 | |
| 15 Aug 2022 | 8-K | Leadership change | 5.02 | |
| 4 Aug 2022 | 8-K | Results | 2.02, 9.01 | |
| 1 Jun 2022 | 8-K | Shareholder vote | 5.07 | |
| 5 May 2022 | 8-K | Results | 2.02, 9.01 | |
| 15 Apr 2022 | 8-K | Leadership change | 5.02 | |
| 14 Mar 2022 | 8-K | Leadership change | 5.02, 9.01 | |
| 24 Feb 2022 | 8-K | Results | 2.02, 9.01 | |
| 4 Nov 2021 | 8-K | Results | 2.02, 9.01 | |
| 5 Aug 2021 | 8-K | Results | 2.02, 9.01 | |
| 22 Jul 2021 | 8-K | Material agreementOther events | 1.01, 8.01, 9.01 | |
| 20 Jul 2021 | 8-K | ResultsOther events | 2.02, 8.01, 9.01 | |
| 28 May 2021 | 8-K | Shareholder vote | 5.07 | |
| 10 May 2021 | 8-K | Leadership change | 5.02, 9.01 |
1–50 of 111
8-K events each year
Hover a column for its exact count
051015
'15'19'23'26
Every filing
The company's filings with the SEC, newest first: 271 held. Insider, fund and large-holder filings have their own tables below.
| 7 Aug 2026 | S-8 | – | |
| 7 Aug 2026 | 10-Q | 30 Jun 2026 | |
| 6 Aug 2026 | 8-K | 6 Aug 2026 | |
| 6 Jul 2026 | 8-K | 1 Jul 2026 | |
| 16 Jun 2026 | 8-K/A | 2 Jun 2026 | |
| 16 Jun 2026 | 8-K | 11 Jun 2026 | |
| 5 Jun 2026 | 8-K | 2 Jun 2026 | |
| 8 May 2026 | 10-Q | 31 Mar 2026 | |
| 7 May 2026 | 8-K | 7 May 2026 | |
| 23 Apr 2026 | ARS | 31 Dec 2025 | |
| 23 Apr 2026 | DEFA14A | – | |
| 23 Apr 2026 | DEF 14A | 11 Jun 2026 | |
| 1 Apr 2026 | 8-K | 26 Mar 2026 | |
| 2 Mar 2026 | S-8 | – | |
| 27 Feb 2026 | 10-K | 31 Dec 2025 | |
| 26 Feb 2026 | 8-K | 26 Feb 2026 | |
| 12 Jan 2026 | 8-K | 11 Jan 2026 | |
| 10 Dec 2025 | S-3ASR | – | |
| 10 Dec 2025 | RW | – | |
| 5 Dec 2025 | S-8 | – | |
| 5 Dec 2025 | S-3 | – | |
| 5 Dec 2025 | 8-K | 4 Dec 2025 | |
| 7 Nov 2025 | 10-Q | 30 Sep 2025 | |
| 6 Nov 2025 | 8-K | 6 Nov 2025 | |
| 21 Oct 2025 | S-8 | – | |
| 8 Aug 2025 | 10-Q | 30 Jun 2025 | |
| 7 Aug 2025 | 8-K | 7 Aug 2025 | |
| 18 Jun 2025 | 8-K | 12 Jun 2025 | |
| 9 May 2025 | 10-Q | 31 Mar 2025 | |
| 8 May 2025 | 8-K | 8 May 2025 | |
| 24 Apr 2025 | ARS | 31 Dec 2024 | |
| 24 Apr 2025 | DEFA14A | – | |
| 24 Apr 2025 | DEF 14A | 12 Jun 2025 | |
| 12 Mar 2025 | 8-K | 6 Mar 2025 | |
| 28 Feb 2025 | S-8 | – | |
| 28 Feb 2025 | 10-K | 31 Dec 2024 | |
| 27 Feb 2025 | 8-K | 27 Feb 2025 | |
| 13 Jan 2025 | 8-K | 12 Jan 2025 | |
| 6 Dec 2024 | 8-K | 2 Dec 2024 | |
| 12 Nov 2024 | 10-Q | 30 Sep 2024 | |
| 12 Nov 2024 | 8-K | 12 Nov 2024 | |
| 9 Aug 2024 | 10-Q | 30 Jun 2024 | |
| 8 Aug 2024 | 8-K | 8 Aug 2024 | |
| 22 Jul 2024 | 8-K | 19 Jul 2024 | |
| 16 Jul 2024 | S-8 | – | |
| 18 Jun 2024 | 8-K | 12 Jun 2024 | |
| 5 Jun 2024 | DEFA14A | – | |
| 10 May 2024 | 10-Q | 31 Mar 2024 | |
| 9 May 2024 | 8-K | 9 May 2024 | |
| 24 Apr 2024 | ARS | 31 Dec 2023 |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 200 | $406.50 | $81.3K | 221,114 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 962 | $408.26 | $392.7K | 220,152 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 627 | $409.89 | $257.0K | 219,525 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 605 | $411.32 | $248.8K | 218,920 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 211 | $412.20 | $87.0K | 218,709 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 125 | $413.05 | $51.6K | 218,584 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 255 | $415.67 | $106.0K | 218,329 | 23 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 165 | $416.67 | $68.8K | 218,164 | 23 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 215 | $399.34 | $85.9K | 8,785 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 280 | $401.29 | $112.4K | 8,505 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 90 | $404.25 | $36.4K | 8,415 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 50 | $405.15 | $20.3K | 8,365 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 35 | $406.62 | $14.2K | 8,330 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 80 | $409.36 | $32.7K | 8,250 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 142 | $398.95 | $56.7K | 8,858 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 280 | $400.68 | $112.2K | 8,578 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 60 | $401.62 | $24.1K | 8,518 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 90 | $403.70 | $36.3K | 8,428 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 80 | $406.06 | $32.5K | 8,348 | 20 Oct 2026 |
| 16 Oct 2026 | Sheena JonathanDirector | Sale under a trading plan | 98 | $409.34 | $40.1K | 8,250 | 20 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 286 | $388.32 | $111.1K | 2,169,108 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 714 | $389.84 | $278.3K | 2,168,394 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 600 | $390.21 | $234.1K | 2,167,794 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 300 | $391.58 | $117.5K | 2,167,494 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 800 | $393.47 | $314.8K | 2,166,694 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 300 | $394.39 | $118.3K | 2,166,394 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 1,900 | $396.30 | $753.0K | 2,164,494 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 1,100 | $397.16 | $436.9K | 2,163,394 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 600 | $398.09 | $238.9K | 2,162,794 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 793 | $399.31 | $316.7K | 2,162,001 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 2,671 | $400.31 | $1.1M | 2,159,330 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 5,974 | $401.42 | $2.4M | 2,153,356 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 6,309 | $402.23 | $2.5M | 2,147,047 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 3,858 | $403.27 | $1.6M | 2,143,189 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 10,321 | $404.64 | $4.2M | 2,132,868 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 6,274 | $405.18 | $2.5M | 2,126,594 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 1,400 | $406.63 | $569.3K | 2,125,194 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 3,800 | $407.27 | $1.5M | 2,121,394 | 16 Oct 2026 |
| 15 Oct 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sale under a trading plan | 2,000 | $408.24 | $816.5K | 2,119,394 | 16 Oct 2026 |
| 1 Oct 2026 | Chapman Steven LeonardCEO AND PRESIDENT | Sale under a trading plan | 1,273 | $413.31 | $526.1K | 96,926 | 2 Oct 2026 |
| 1 Oct 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sale under a trading plan | 200 | $411.62 | $82.3K | 109,714 | 2 Oct 2026 |
| 1 Oct 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sale under a trading plan | 954 | $413.11 | $394.1K | 108,760 | 2 Oct 2026 |
| 1 Oct 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sale under a trading plan | 1,846 | $415.07 | $766.2K | 106,914 | 2 Oct 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 400 | $385.10 | $154.0K | 17,632 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 2,175 | $386.71 | $841.1K | 15,457 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 2,734 | $387.65 | $1.1M | 12,723 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 1,293 | $388.71 | $502.6K | 11,430 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 2,320 | $389.69 | $904.1K | 9,110 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 110 | $390.42 | $42.9K | 9,000 | 25 Sep 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | Sale under a trading plan | 390 | $385.29 | $150.3K | 17,642 | 25 Sep 2026 |
1–50 of 150
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 27 Oct 2026 | JONATHAN SHEENADIRECTOR | 287 | $116.2K | 27 Oct 2026 |
| 27 Oct 2026 | JOHN FESKOOFFICER | 771 | $312.2K | 27 Oct 2026 |
| 27 Oct 2026 | MICHAEL BROPHYOFFICER | 771 | $312.2K | 27 Oct 2026 |
| 27 Oct 2026 | DANIEL RABINOWITZOFFICER | 873 | $353.5K | 27 Oct 2026 |
| 27 Oct 2026 | SOLOMON MOSHKEVICHOFFICER | 997 | $403.7K | 27 Oct 2026 |
| 27 Oct 2026 | MATTHEW RABINOWITZDIRECTOR | 1,697 | $687.1K | 27 Oct 2026 |
| 27 Oct 2026 | STEVEN CHAPMANOFFICER, DIRECTOR | 2,236 | $905.4K | 27 Oct 2026 |
| 21 Oct 2026 | Sheena JonathanDirector | 9,450 | $3.9M | 21 Oct 2026 |
| 15 Oct 2026 | MATTHEW RABINOWITZDirector, Officer | 50,000 | $19.7M | 15 Oct 2026 |
| 1 Oct 2026 | STEVEN L CHAPMANOfficer, Director | 1,273 | $526.1K | 1 Oct 2026 |
| 1 Oct 2026 | SOLOMON MOSHKEVICHOfficer | 3,000 | $1.2M | 1 Oct 2026 |
| 23 Sep 2026 | Sheena JonathanDirector | 21,064 | $8.2M | 23 Sep 2026 |
| 15 Sep 2026 | TINKERBELLE II TR U/A DTD 10/22/2021Officer, Director | 2,000 | $700.0K | 15 Sep 2026 |
| 11 Sep 2026 | MATTHEW RABINOWITZDirector, Officer | 200,000 | $65.2M | 11 Sep 2026 |
| 2 Sep 2026 | SOLOMON MOSHKEVICHOFFICER | 0 | $0 | 2 Sep 2026 |
| 1 Sep 2026 | STEVEN L CHAPMANOfficer, Director | 1,698 | $545.0K | 1 Sep 2026 |
| 1 Sep 2026 | SOLOMON MOSHKEVICHOfficer | 3,000 | $962.2K | 1 Sep 2026 |
| 7 Aug 2026 | TINKERBELLE II TR U/A DTD 10/22/2021Officer, Director | 2,000 | $641.8K | 7 Aug 2026 |
| 7 Aug 2026 | Sheena JonathanDirector | 18,000 | $6.0M | 7 Aug 2026 |
| 4 Aug 2026 | MICHAEL BROPHYOfficer | 478 | $129.2K | 4 Aug 2026 |
| 3 Aug 2026 | JONATHAN SHEENAOFFICER | 108 | $28.9K | 3 Aug 2026 |
| 3 Aug 2026 | JOHN FESKOOFFICER | 292 | $78.2K | 3 Aug 2026 |
| 3 Aug 2026 | MICHAEL BROPHYOFFICER | 313 | $83.8K | 3 Aug 2026 |
| 3 Aug 2026 | DANIEL RABINOWITZOFFICER | 330 | $88.4K | 3 Aug 2026 |
| 3 Aug 2026 | SOLOMON MOSHKEVICHOFFICER | 405 | $108.4K | 3 Aug 2026 |
| 3 Aug 2026 | MATTHEW RABINOWITZOFFICER, DIRECTOR | 722 | $193.3K | 3 Aug 2026 |
| 3 Aug 2026 | STEVEN CHAPMANOFFICER, DIRECTOR | 1,167 | $312.5K | 3 Aug 2026 |
| 3 Aug 2026 | STEVEN L CHAPMANOfficer, Director | 1,894 | $502.7K | 3 Aug 2026 |
| 3 Aug 2026 | SOLOMON MOSHKEVICHOfficer | 3,000 | $795.8K | 3 Aug 2026 |
| 29 Jul 2026 | MICHAEL BROPHYOfficer | 1,863 | $469.9K | 29 Jul 2026 |
| 28 Jul 2026 | JONATHAN SHEENADIRECTOR | 188 | $48.5K | 28 Jul 2026 |
| 28 Jul 2026 | JOH N FESKOOFFICER | 917 | $236.6K | 28 Jul 2026 |
| 28 Jul 2026 | DANIEL RABINOWITZOFFICER | 988 | $254.9K | 28 Jul 2026 |
| 28 Jul 2026 | MICHAEL BROPHYOfficer | 1,178 | $304.0K | 28 Jul 2026 |
| 28 Jul 2026 | SOLOMON MOSHKEVICHOFFICER | 1,185 | $305.8K | 28 Jul 2026 |
| 28 Jul 2026 | MICHAEL BROPHYOFFICER | 1,222 | $315.3K | 28 Jul 2026 |
| 28 Jul 2026 | STEVEN CHAPMANOFFICER, DIRECTOR | 3,525 | $909.6K | 28 Jul 2026 |
| 27 Jul 2026 | JONATHAN SHEENADIRECTOR | 285 | $74.7K | 27 Jul 2026 |
| 27 Jul 2026 | JOHN FESKOOFFICER | 772 | $202.3K | 27 Jul 2026 |
| 27 Jul 2026 | MICHAEL BROPHYOFFICER | 772 | $202.3K | 27 Jul 2026 |
| 27 Jul 2026 | DANIEL RABINOWITZOFFICER | 873 | $228.7K | 27 Jul 2026 |
| 27 Jul 2026 | SOLOMON MOSHKEVICHOFFICER | 998 | $261.5K | 27 Jul 2026 |
| 27 Jul 2026 | MATTHEW RABINOWITZDIRECTOR, OFFICER | 1,697 | $444.6K | 27 Jul 2026 |
| 27 Jul 2026 | STEVEN CHAPMANOFFICER, DIRECTOR | 2,163 | $566.7K | 27 Jul 2026 |
| 15 Jul 2026 | ROWAN EMMA CHAPMANDirector | 135 | $37.1K | 15 Jul 2026 |
| 15 Jul 2026 | Sheena JonathanDirector | 1,500 | $412.8K | 15 Jul 2026 |
| 13 Jul 2026 | Sheena JonathanDirector | 9,450 | $2.5M | 13 Jul 2026 |
| 6 Jul 2026 | TINKERBELLE II TR U/A DTD 10/22/2021Officer, Director | 1,000 | $280.0K | 6 Jul 2026 |
| 1 Jul 2026 | SOLOMON MOSHKEVICHOfficer | 3,000 | $818.7K | 1 Jul 2026 |
| 1 Jul 2026 | DANIEL RABINOWITZOfficer | 16,800 | $4.6M | 1 Jul 2026 |
1–50 of 80
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 14 Aug 2026 | T. Rowe Price Associates, Inc. | 13G amended | 6.3% | 9.0M |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.08% | 7.2M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | T. Rowe Price Associates, Inc. | 13G amended | 7.8% | 10.9M |
| 23 Jan 2026 | JPMORGAN CHASE & CO. | 13G amended | 9.1% | 12.8M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
| 22 Sep 2025 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 15 Oct 2025 |
| 22 Aug 2025 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 5 Sep 2025 |
| 22 Jul 2025 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 11 Aug 2025 |
| 20 Nov 2024 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 5 Dec 2024 |
| 10 Apr 2023 | Daniel GoldmanNY10 | Sale (partial) | $1,001 - $15,000 | Self | 19 May 2023 |
| 6 Mar 2023 | Daniel GoldmanNY10 | Purchase | $1,001 - $15,000 | Self | 17 Apr 2023 |
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 5.9M | -7.92% | 3.43 |
| 30 Sep 2026 | 6.4M | +32.48% | 3.2 |
| 15 Sep 2026 | 4.8M | -13% | 4.7 |
| 31 Aug 2026 | 5.5M | +28.38% | 4.37 |
| 14 Aug 2026 | 4.3M | -1.6% | 2.61 |
| 31 Jul 2026 | 4.4M | -12.07% | 4.69 |
| 15 Jul 2026 | 5.0M | -14.71% | 3.61 |
| 30 Jun 2026 | 5.8M | +34.89% | 2.75 |
| 15 Jun 2026 | 4.3M | +19.36% | 4 |
| 29 May 2026 | 3.6M | -4.47% | 2.23 |
1–10 of 138
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
917
quarter to 30 Jun 2026
Added or new
485
since 31 Mar 2026
Trimmed
240
in the quarter
Largest holder
JPMorgan Chase & Co.
$3.5B
The 60 largest of 917 funds, by value
| JPMorgan Chase & Co. | $3.5B | 12.9M | -521.3K | Trimmed | 0.20% | Filing ↗ |
| BlackRock, Inc. | $3.0B | 10.9M | +237.3K | Added | 0.04% | Filing ↗ |
| Price T Rowe Associates Inc. | $2.4B | 9.0M | -3.2M | Trimmed | 0.25% | Filing ↗ |
| Vanguard Capital Management LLC | $1.7B | 6.2M | +219.7K | Added | 0.04% | Filing ↗ |
| Vanguard Portfolio Management LLC | $1.6B | 5.8M | +137.9K | Added | 0.07% | Filing ↗ |
| FMR LLC | $1.5B | 5.5M | +2.9M | Added | 0.06% | Filing ↗ |
| Wellington Management Group LLP | $1.1B | 4.0M | -727.9K | Trimmed | 0.19% | Filing ↗ |
| State Street Corp. | $992.3M | 3.7M | +238.1K | Added | 0.03% | Filing ↗ |
| Duquesne Family Office LLC | $864.9M | 3.2M | +122.7K | Added | 19.86% | Filing ↗ |
| Geode Capital Management, LLC | $744.6M | 2.8M | -25.9K | Trimmed | 0.04% | Filing ↗ |
| Franklin Resources Inc. | $739.9M | 2.7M | +240.6K | Added | 0.16% | Filing ↗ |
| Castle Hook Partners LP | $704.8M | 2.6M | +66.5K | Added | 7.55% | Filing ↗ |
| Coatue Management LLC | $680.0M | 2.5M | -36.8K | Trimmed | 1.40% | Filing ↗ |
| AQR Capital Management LLC | $628.1M | 2.3M | +70.6K | Added | 0.22% | Filing ↗ |
| Farallon Capital Management, L.l.c. | $602.2M | 2.2M | -989.0K | Trimmed | 3.55% | Filing ↗ |
| Massachusetts Financial Services Co. | $535.1M | 2.0M | -68.7K | Trimmed | 0.17% | Filing ↗ |
| Norges Bank | $496.2M | 1.8M | – | Held | 0.05% | Filing ↗ |
| Fred Alger Management, LLC | $482.6M | 1.8M | +21.5K | Added | 1.61% | Filing ↗ |
| Goldman Sachs Group Inc. | $466.9M | 1.7M | +952.9K | Added | 0.05% | Filing ↗ |
| Sofinnova Investments, Inc. | $420.8M | 1.6M | 0 | Held | 22.48% | Filing ↗ |
| Capital World Investors | $408.4M | 1.5M | +36.4K | Added | 0.05% | Filing ↗ |
| Arrowstreet Capital, Limited Partnership | $408.2M | 1.5M | +312.0K | Added | 0.18% | Filing ↗ |
| Maverick Capital Ltd | $368.3M | 1.4M | +185.0K | Added | 3.32% | Filing ↗ |
| D. E. Shaw & Co., Inc. | $347.3M | 1.3M | +787.9K | Added | 0.23% | Filing ↗ |
| Morgan Stanley | $345.9M | 1.3M | -80.0K | Trimmed | 0.02% | Filing ↗ |
| Federated Hermes, Inc. | $309.2M | 1.1M | +48.9K | Added | 0.45% | Filing ↗ |
| T. Rowe Price Investment Management, Inc. | $305.0M | 1.1M | -7.1K | Trimmed | 0.20% | Filing ↗ |
| Clearbridge Investments, LLC | $276.4M | 1.0M | +125.0K | Added | 0.23% | Filing ↗ |
| RTW Investments, LP | $271.4M | 1.0M | -250.0K | Trimmed | 2.32% | Filing ↗ |
| Jane Street Group, LLC | $251.6M | 927.0K | +663.3K | Added | 0.16% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $249.4M | 918.6K | +46.0K | Added | 0.06% | Filing ↗ |
| Invesco Ltd. | $237.1M | 873.3K | -385.0K | Trimmed | 0.02% | Filing ↗ |
| Northern Trust Corp. | $227.1M | 836.5K | +48.1K | Added | 0.03% | Filing ↗ |
| UBS AM, a distinct business unit of UBS Asset Management Americas LLC | $226.2M | 833.4K | +80.4K | Added | 0.04% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $218.9M | 806.5K | +93.8K | Added | 0.03% | Filing ↗ |
| Nwi Management LP | $207.0M | 762.6K | -762.6K | Trimmed | 13.23% | Filing ↗ |
| Bank of America Corp. | $200.0M | 736.6K | +3.0K | Added | 0.01% | Filing ↗ |
| Westfield Capital Management Co. LP | $197.2M | 726.6K | -28.1K | Trimmed | 0.64% | Filing ↗ |
| ARK Investment Management LLC | $187.0M | 688.9K | +4.6K | Added | 1.21% | Filing ↗ |
| Sumitomo Mitsui Trust Group, Inc. | $174.7M | 643.6K | -48.7K | Trimmed | 0.10% | Filing ↗ |
| Chevy Chase Trust Holdings, LLC | $162.8M | 599.9K | +12.8K | Added | 0.42% | Filing ↗ |
| Raymond James Financial Inc. | $161.0M | 593.1K | +2.0K | Added | 0.04% | Filing ↗ |
| Worldquant Millennium Advisors LLC | $160.6M | 591.5K | +235.0K | Added | 0.55% | Filing ↗ |
| UBS Group AG | $150.3M | 553.7K | +130.8K | Added | 0.02% | Filing ↗ |
| Legal & General Group Plc | $150.1M | 553.1K | +55.0K | Added | 0.03% | Filing ↗ |
| Bank of New York Mellon Corp | $149.3M | 549.9K | -119.8K | Trimmed | 0.03% | Filing ↗ |
| First Trust Advisors LP | $138.8M | 511.2K | -17.6K | Trimmed | 0.08% | Filing ↗ |
| Wells Fargo & Company | $136.5M | 502.8K | +93.7K | Added | 0.02% | Filing ↗ |
| Assenagon Asset Management S.A. | $136.2M | 501.7K | – | Held | 0.09% | Filing ↗ |
| Nuveen, LLC | $135.5M | 499.1K | +24.5K | Added | 0.03% | Filing ↗ |
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Natera, Inc.this company | $59.0B | $2.7B | 37.8% | -10.7% | -7.1% | -10.6% | – | – |
| Labcorp Holdings Inc. | $26.8B | $14.3B | 6.4% | 10.4% | 7.0% | 11.6% | 27.4× | 14.8× |
| Quest Diagnostics Inc. | $26.7B | $11.8B | 9.1% | 14.6% | 9.5% | 14.8% | 24.2× | 13.6× |
| Guardant Health, Inc. | $23.8B | $1.2B | 42.7% | -39.7% | -38.3% | – | – | – |
| Caris Life Sciences, Inc. | $9.5B | $989.6M | – | 15.5% | 10.6% | 17.8% | 93.6× | 53.0× |
| Grail, Inc. | $6.7B | $165.3M | 23.1% | -338.4% | -236.9% | -15.4% | – | – |
| RadNet, Inc. | $5.8B | $2.3B | 18.9% | 3.1% | -0.9% | -1.9% | – | 26.4× |
| Veracyte, Inc. | $4.1B | $561.9M | 17.3% | 18.8% | 20.4% | 8.2% | 35.8× | 29.6× |
| CareDx, Inc. | $3.6B | $458.1M | 34.4% | 23.6% | 24.2% | 26.1% | 34.1× | 26.6× |
| Fortrea Holdings Inc. | $2.3B | $2.7B | -2.1% | -0.4% | -3.2% | -16.3% | – | 47.5× |
| Personalis, Inc. | $1.7B | $69.7M | -13.3% | -164.1% | -153.8% | -45.6% | – | – |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence